Clinical protocols to monitor efficacy of [ 177 Lu]Lu-PSMA radiopharmaceutical therapy in metastatic castration-resistant prostate cancer.

Authors: Unterrainer, Lena, De Leiris, NIcolas, Unterrainer, Marcus, Ilhan, Harun, Delker, Astrid, Hempel, Linus, Ells, Zachary, Zahner, Joseph, Holzgreve, Adrien, Zacherl, Mathias J., Casuscelli, Jozefina, Kiraz, Kevin, Leenhardt, Julien, Jacquet, Emmanuelle, Long, Jerome, Laramas, Mathieu, Paller, Channing Judith, Solnes, Lilja B, Gafita, Andrei, Djaileb, Loic

Source: Journal of Clinical Oncology; 2/20/2025 Supplement 5, Vol. 43, p39-39, 288p

Prognostic value of quantitative PSMA-PET parameters during chemotherapy in prostate cancer.

Authors: Skawran, Stephan, Gafita, Andrei, Lorenzini, Theo, Hoberück, Sebastian, Mattana, Francesco, Di Giorgio, Andrea, Miederer, Matthias, Paller, Channing Judith, Djaileb, Loic, Solnes, Lilja B, Farolfi, Andrea, Ceci, Francesco, Eiber, Matthias, Voter, Andrew F

Source: Journal of Clinical Oncology; 2/20/2025 Supplement 5, Vol. 43, p33-33, 288p

Navigating the unseen peril: safeguarding medical imaging in the age of AI.

Authors: Maertens, Alexandra, Brykman, Steve, Hartung, Thomas, Gafita, Andrei, Bai, Harrison, Hoelzer, David, Skoudis, Ed, Paller, Channing Judith

Source: Frontiers in Artificial Intelligence; 2024, p1-10, 10p

Blood-based markers of differential efficacy of bipolar androgen therapy and enzalutamide in the randomized TRANSFORMER trial.

Authors: Denmeade, Samuel R., Antonarakis, Emmanuel S., Paller, Channing Judith, Markowski, Mark Christopher, Marshall, Catherine Handy, Wang, Hao, Tsai, Hua-Ling, Kanayama, Mayuko, Lu, Changxue, Rabizadeh, Daniel, Schumacher, Megan, Luo, Jun

Source: Journal of Clinical Oncology; 2024 Supplement 17, Vol. 42, pLBA5014-LBA5014, 83p

A phase 2 study of neoadjuvant PARP inhibition followed by radical prostatectomy (RP) in patients with unfavorable intermediate-risk or high-risk prostate cancer with BRCA1/2 gene alterations (NePtune).

Authors: McKay, Rana R., Liu, Lin, Pu, Minya, Araneta, Arlene, Wang, Luke, Castano, Neremiah, Gomez, Jennifer, Ajmera, Archana, Ye, Huihui, Pili, Roberto, Runcie, Karie, McHugh, Deaglan Joseph, Offit, Kenneth, Paller, Channing Judith, Haas, Naomi B., Javier-Desloges, Juan, Kane, Christopher J., Seibert, Tyler M, Bagrodia, Aditya

Source: Journal of Clinical Oncology; 2024 Supplement 4, Vol. 42, pTPS353-TPS353, 97p

Muscadine grape skin extract in men with biochemically recurrent prostate cancer: A phase III, randomized, multicenter, placebo-controlled clinical trial.

Authors: Mandl, Adel, Zahurak, Marianna, Sfanos, Karen, Metri, Nicole, Maughan, Benjamin L., Taplin, Mary-Ellen, Shore, Neal D., McKay, Rana R., Reichert, Zachery R, Szmulewitz, Russell Zelig, Kessler, Elizabeth R., Heath, Elisabeth I., Dreicer, Robert, Stein, Cy Aaron, Marshall, Catherine Handy, Markowski, Mark Christopher, Denmeade, Samuel R., Antonarakis, Emmanuel S., Carducci, Michael Anthony, Paller, Channing Judith

Source: Journal of Clinical Oncology; 2024 Supplement 4, Vol. 42, p329-329, 97p

BRCAAway: A randomized phase 2 trial of abiraterone, olaparib, or abiraterone + olaparib in patients with metastatic castration-resistant prostate cancer (mCRPC) bearing homologous recombination-repair mutations (HRRm).

Authors: Hussain, Maha H. A., Kocherginsky, Masha, Agarwal, Neeraj, Adra, Nabil, Zhang, Jingsong, Paller, Channing Judith, Picus, Joel, Reichert, Zachery R, Szmulewitz, Russell Zelig, Tagawa, Scott T., Kuzel, Timothy, Bazzi, Latifa, Daignault-Newton, Stephanie, Whang, Young E., Dreicer, Robert, Stephenson, Ryan D., Rettig, Matthew, Shevrin, Daniel, Chinnaiyan, Arul, Antonarakis, Emmanuel S.

Source: Journal of Clinical Oncology; 2024 Supplement 4, Vol. 42, p19-19, 235p

Germline BRCA2, ATM and CHEK2 alterations shape somatic mutation landscapes in prostate cancer.

Authors: Nakazawa, Mari, Fang, Mike, Lotan, Tamara L., Luo, Jun, Isaacs, William B., Paller, Channing Judith, Antonarakis, Emmanuel S.

Source: Journal of clinical oncology. 40(6 suppl):148-148

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100155645452.0x000001&indx=1&recIds=ETOCvdc_100155645452.0x000001

A systematic review of immune checkpoint inhibitors (ICI) in non-clear cell renal cell cancer (nccRCC) subtypes.

Authors: Reis, Ana Filipa, Odeny, Thomas A, Simão, Diana, Fontes-Sousa, Mario, Rodrigues, Ysel Chiara Vina, Paller, Channing Judith, Barata, Pedro C.

Source: Journal of clinical oncology. 40(6 suppl):353-353

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100152990184.0x000001&indx=1&recIds=ETOCvdc_100152990184.0x000001

Virtual genetics board for enhancing knowledge and practice of prostate cancer genetic testing: The ENGAGEMENT study.

Authors: Giri, Veda N., Gross, Laura, Cheng, Heather H., Russo, Jessica, Paller, Channing Judith, Johnson, Jennifer M, Weg, Emily Steinberger, Loeb, Stacy

Source: Journal of clinical oncology. 40(6 suppl):184-184

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100152983254.0x000001&indx=1&recIds=ETOCvdc_100152983254.0x000001

PROMISE Registry: A prostate cancer registry of outcomes and germline mutations for improved survival and treatment effectiveness.

Authors: Paller, Channing Judith, Lorentz, Justin, DeMarco, Tiffani, Stadler, Walter Michael, Armstrong, Andrew J., Taplin, Mary-Ellen, Hussain, Maha H. A., Pili, Roberto, Mao, Shifeng S., Elrod, Jo Ann, Sokolova, Alexandra, Heath, Elisabeth I., McKay, Rana R., Vinson, Jake, Green, Rebecca, Tran, Christina, Macario, Natalie, Cook, Audrey, Chiang, Jenny, Cheng, Heather H.

Source: Journal of clinical oncology. 40(6 suppl):TPS191-TPS191

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100152983647.0x000001&indx=1&recIds=ETOCvdc_100152983647.0x000001

The somatic mutation landscape of germline CHEK2-altered prostate cancer.

Authors: Nizialek, Emily, Lotan, Tamara L., Isaacs, William B., Yegnasubramanian, Srinivasan, Paller, Channing Judith, Antonarakis, Emmanuel S.

Source: Journal of clinical oncology. 39(15 suppl):5084-5084

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100173205259.0x000001&indx=1&recIds=ETOCvdc_100173205259.0x000001

COMBAT-CRPC: Concurrent administration of bipolar androgen therapy (BAT) and nivolumab in men with metastatic castration-resistant prostate cancer (mCRPC).

Authors: Markowski, Mark Christopher, Taplin, Mary-Ellen, Aggarwal, Rahul Raj, Wang, Hao, Lalji, Aliya, Paller, Channing Judith, Marshall, Catherine Handy, Carducci, Michael Anthony, Eisenberger, Mario A., De Marzo, Angelo M, Denmeade, Samuel R., Antonarakis, Emmanuel S.

Source: Journal of clinical oncology. 39(15 suppl):5014-5014

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100173204354.0x000001&indx=1&recIds=ETOCvdc_100173204354.0x000001

Interim results of aasur: A single arm, multi-center phase 2 trial of apalutamide (A) + abiraterone acetate + prednisone (AA+P) + leuprolide with stereotactic ultra-hypofractionated radiation (UHRT) in very high risk (VHR), node negative (N0) prostate cancer (PCa).

Authors: McBride, Sean Matthew, Spratt, Daniel Eidelberg, Kollmeier, Marisa, Abida, Wassim, Xiao, Han, Slovin, Susan F., Paller, Channing Judith, Deville, Curtiland, Den, Robert Benjamin, Hearn, Jason W.D., Scher, Howard I., Zelefsky, Michael J., Rathkopf, Dana E.

Source: Journal of clinical oncology. 39(15 suppl):5012-5012

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100173204303.0x000001&indx=1&recIds=ETOCvdc_100173204303.0x000001

SWOG S1216: A phase III randomized trial comparing androgen deprivation therapy (ADT) plus TAK-700 with ADT plus bicalutamide in patients (pts) with newly diagnosed metastatic hormone-sensitive prostate cancer (mHSPC) (NCT01809691).

Authors: Agarwal, Neeraj, Tangen, Catherine, Hussain, Maha H. A., Gupta, Shilpa, Plets, Melissa, Lara, Primo "Lucky" N., Harzstark, Andrea, Twardowski, Przemyslaw, Paller, Channing Judith, Zylla, Dylan M., Zibelman, Matthew R., Levine, Ellis Glenn, Roth, Bruce J., Goldkorn, Amir, Vaena, Daniel A., Kohli, Manish, Crispino, Tony, Vogelzang, Nicholas J., Thompson, Ian Murchie, Quinn, David I.

Source: Journal of clinical oncology. 39(15 suppl):5001-5001

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100173204212.0x000001&indx=1&recIds=ETOCvdc_100173204212.0x000001

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.

Whole-food plant-based diet (WFPBD) to control weight and metabo-inflammation in overweight/obese men with prostate cancer (PC) receiving androgen deprivation therapy (ADT): A multi-center randomized control trial.

Authors: Jacobs, Nicole, Hootman, Katie, Fischer, Victoria, Pinnavaia, Nadja, Sfanos, Karen, Nauseef, Jones T., Molina, Ana M., Sternberg, Cora N., Tagawa, Scott T., Ballman, Karla V., Stein, Mark N., Paller, Channing Judith, Nanus, David M.

Source: Journal of Clinical Oncology; 2023 Supplement 16, Vol. 41, pTPS5098-TPS5098, 1p

Randomized placebo-controlled trial of intravenous vitamin C plus docetaxel in metastatic prostate cancer.

Authors: Paller, Channing Judith, Zahurak, Marianna, Heath, Elisabeth I., Kelly, William Kevin, Hoimes, Christopher J., Taksey, Jason David, Marshall, Catherine Handy, Markowski, Mark Christopher, Barata, Pedro C., Rudek, Michelle A., Nauroth, Julie, Wang, Lin, Durham, Jennifer N., Eisenberger, Mario A., Carducci, Michael Anthony, Denmeade, Samuel R., Levine, Mark

Source: Journal of Clinical Oncology; 2023 Supplement 16, Vol. 41, pe17050-e17050, 1p